Circulating tumor DNA as an early cancer detection tool.

[1]  David R. Jones,et al.  High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants , 2019, Nature Medicine.

[2]  S. Chin,et al.  Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer , 2019, Science Translational Medicine.

[3]  H. Nielsen,et al.  Genome-wide cell-free DNA fragmentation in patients with cancer , 2019, Nature.

[4]  Edith M. Ross,et al.  The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer , 2019, Cell reports.

[5]  Alex Root,et al.  Mathematical Modeling of The Challenge to Detect Pancreatic Adenocarcinoma Early with Biomarkers , 2019, Challenges.

[6]  H. Kocher,et al.  Pancreatic Cancer , 2019, Methods in Molecular Biology.

[7]  Sharyn I. Katz,et al.  Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer , 2019, JAMA oncology.

[8]  M. Speicher,et al.  Current and future perspectives of liquid biopsies in genomics-driven oncology , 2018, Nature Reviews Genetics.

[9]  Keval Patel,et al.  Enhanced detection of circulating tumor DNA by fragment size analysis , 2018, Science Translational Medicine.

[10]  G. Sonpavde,et al.  Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  E. Diamandis,et al.  Utility of circulating tumor DNA in cancer diagnostics with emphasis on early detection , 2018, BMC Medicine.

[12]  E. Diamandis,et al.  Circulating Tumor DNA for Early Cancer Detection. , 2018, The journal of applied laboratory medicine.

[13]  Benjamin Werner,et al.  Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial. , 2018, Cancer discovery.

[14]  H. Ren,et al.  Blood-based DNA Methylation Biomarkers for Early Detection of Colorectal Cancer , 2018, Journal of proteomics & bioinformatics.

[15]  C. Paweletz,et al.  False-Positive Plasma Genotyping Due to Clonal Hematopoiesis , 2018, Clinical Cancer Research.

[16]  Ludmila V. Danilova,et al.  Detection and localization of surgically resectable cancers with a multi-analyte blood test , 2018, Science.

[17]  H. Ikeuchi,et al.  A Panel of Methylated MicroRNA Biomarkers for Identifying High-Risk Patients With Ulcerative Colitis-Associated Colorectal Cancer. , 2017, Gastroenterology.

[18]  C. Gau,et al.  Somatic TP53 variants frequently confound germline testing results , 2017, Genetics in Medicine.

[19]  M. Plebanski,et al.  Autoantibodies against HSF1 and CCDC155 as Biomarkers of Early-Stage, High-Grade Serous Ovarian Cancer , 2017, Cancer Epidemiology, Biomarkers & Prevention.

[20]  Charles A Powell,et al.  Evaluating Molecular Biomarkers for the Early Detection of Lung Cancer: When Is a Biomarker Ready for Clinical Use? An Official American Thoracic Society Policy Statement , 2017, American journal of respiratory and critical care medicine.

[21]  G. Lyman,et al.  Comparison of 2 Commercially Available Next-Generation Sequencing Platforms in Oncology , 2017, JAMA oncology.

[22]  Sharon S. Hori,et al.  A Model-Based Personalized Cancer Screening Strategy for Detecting Early-Stage Tumors Using Blood-Borne Biomarkers. , 2017, Cancer research.

[23]  Ashwini Naik,et al.  Phylogenetic ctDNA analysis depicts early stage lung cancer evolution , 2017, Nature.

[24]  Mark Lee,et al.  Next-Generation Sequencing of Circulating Tumor DNA for Early Cancer Detection , 2017, Cell.

[25]  M. Kerin,et al.  Circulating Nucleosomes and Nucleosome Modifications as Biomarkers in Cancer , 2017, Cancers.

[26]  Y. Toiyama,et al.  Diagnostic Potential of Cell-Free and Exosomal MicroRNAs in the Identification of Patients with High-Risk Colorectal Adenomas , 2016, PloS one.

[27]  D. Bowtell,et al.  Blood Worth Bottling: Circulating Tumor DNA as a Cancer Biomarker. , 2016, Cancer research.

[28]  Cheng Qian,et al.  Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer , 2016, Oncotarget.

[29]  Jiong Wu,et al.  Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 (MALAT1) interacts with estrogen receptor and predicted poor survival in breast cancer , 2016, Oncotarget.

[30]  Yongzhao Shao,et al.  Mathematical Modeling of Therapy-induced Cancer Drug Resistance: Connecting Cancer Mechanisms to Population Survival Rates , 2016, Scientific Reports.

[31]  A. Torkamani,et al.  Assessment of circulating copy number variant detection for cancer screening , 2016, bioRxiv.

[32]  H. Burke.  Predicting Clinical Outcomes Using Molecular Biomarkers , 2016, Biomarkers in cancer.

[33]  A. Krainer,et al.  Abstract PR11: Differentiation of mammary tumors and reduction in metastasis upon Malat1 LncRNA loss , 2016 .

[34]  Carlos Caldas,et al.  Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer , 2015, Nature Communications.

[35]  P. Neven,et al.  Presymptomatic Identification of Cancers in Pregnant Women During Noninvasive Prenatal Testing. , 2015, JAMA oncology.

[36]  M. Otsuka,et al.  Circulating RNAs as new biomarkers for detecting pancreatic cancer. , 2015, World journal of gastroenterology.

[37]  J. Garber,et al.  Noninvasive Prenatal Testing and Incidental Detection of Occult Maternal Malignancies. , 2015, JAMA.

[38]  G. Hannum,et al.  Detection of fetal subchromosomal abnormalities by sequencing circulating cell-free DNA from maternal plasma. , 2015, Clinical chemistry.

[39]  A. Schetter,et al.  Identification of a metastasis-specific MicroRNA signature in human colorectal cancer. , 2015, Journal of the National Cancer Institute.

[40]  G. Nagaraju,et al.  MicroRNAs as biomarkers and prospective therapeutic targets in colon and pancreatic cancers , 2015, Tumor Biology.

[41]  M. McCarthy,et al.  Age-related clonal hematopoiesis associated with adverse outcomes. , 2014, The New England journal of medicine.

[42]  M. Genuardi,et al.  MLH1 constitutional and somatic methylation in patients with MLH1 negative tumors fulfilling the revised Bethesda criteria , 2014, Epigenetics.

[43]  R. Grivell,et al.  Noninvasive prenatal testing. , 2014, Australian family physician.

[44]  L. Diaz,et al.  Liquid biopsies: genotyping circulating tumor DNA. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  M. Choti,et al.  Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.

[46]  Peiyong Jiang,et al.  Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing , 2013, Proceedings of the National Academy of Sciences.

[47]  Y. Toiyama,et al.  Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. , 2013, Journal of the National Cancer Institute.

[48]  Carlos Caldas,et al.  Analysis of circulating tumor DNA to monitor metastatic breast cancer. , 2013, The New England journal of medicine.

[49]  Sanjiv S Gambhir,et al.  Mathematical Model Identifies Blood Biomarker–Based Early Cancer Detection Strategies and Limitations , 2011, Science Translational Medicine.

[50]  Hwee Tong Tan,et al.  Serum autoantibodies as biomarkers for early cancer detection , 2009, The FEBS journal.

[51]  X. Breakefield,et al.  Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer , 2009, British Journal of Cancer.

[52]  Sanjiv S Gambhir,et al.  Cancer Screening: A Mathematical Model Relating Secreted Blood Biomarker Levels to Tumor Sizes , 2008, PLoS medicine.

[53]  William E. Grizzle,et al.  Murine Mammary Carcinoma Exosomes Promote Tumor Growth by Suppression of NK Cell Function1 , 2006, The Journal of Immunology.

[54]  F. F. Madrid,et al.  Autoantibodies in breast cancer sera: candidate biomarkers and reporters of tumorigenesis. , 2005 .

[55]  J. Chin,et al.  Tumor exosomes expressing Fas ligand mediate CD8+ T-cell apoptosis , 2005 .

[56]  M S Pepe,et al.  Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.

[57]  V A Memoli,et al.  Soluble normal and mutated DNA sequences from single-copy genes in human blood. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[58]  P Mandel,et al.  Les acides nucleiques du plasma sanguin chez l' homme , 1948 .